Mozobil Disease Interactions
There are 3 disease interactions with Mozobil (plerixafor).
Plerixafor (applies to Mozobil) leukocytosis
Moderate Potential Hazard, Moderate plausibility.
The use of plerixafor in combination with granulocyte-colony stimulating factor increases leukocytes as well as hematopoietic stem cells populations. Caution should be exercised when administering this agent to patients with peripheral blood neutrophil counts above 50,000/mcL. It is recommended to monitor white blood cell counts during therapy.
Plerixafor (applies to Mozobil) renal impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
It is recommended to reduce the dose of plerixafor by one-third to 0.16 mg/kg in patients with moderate to severe renal impairment.
Plerixafor (applies to Mozobil) thrombocytopenia
Moderate Potential Hazard, Moderate plausibility.
The use of plerixafor may cause thrombocytopenia. Care and close monitoring are recommended when using plerixafor in patients with thrombocytopenia. Monitor counts in all patients and then undergo apheresis.
Switch to professional interaction data
Report options
More about Mozobil (plerixafor)
- Mozobil consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- FDA approval history
- Drug class: hematopoietic stem cell mobilizer
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Pomalyst
Pomalyst (pomalidomide) is used to treat multiple myeloma and AIDS-related Kaposi sarcoma. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.